Use of mimetic peptide containing fibrinogen rgd motif in preparation of medications for preventing and/or treating parkinson's disease

Abstract

This disclosure belongs to the technical field of biomedicine, and discloses use of a mimetic peptide containing a fibrinogen RGD motif in preparation of medications for preventing and/or treating Parkinson's disease. A sequence of the mimetic peptide containing the fibrinogen RGD motif of this disclosure is: Gly-Arg-Gly-Asp-Ser-Pro-Leu-Ala-Pro-Ser-Cys. The applicant of this disclosure has found through research that there is abnormal accumulation of FG in substantia nigra pars compacta of PD mice, and that excessively accumulated FG in the brain may promote abnormal aggregation of α-syn in dopaminergic neurons under mediation of αvβ3 integrin receptor. The mimetic peptide provided by this disclosure can effectively inhibit the abnormal aggregation of α-syn in the dopaminergic neurons and death of the dopaminergic neurons caused by the abnormally accumulated FG in the brain, improve a motion ability of MPTP-modeled PD mice, and provide a new target and idea for PD treatment.

Dependencies are inferred from the claim text.